GUST

CompletedPhase NA

Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy

Lead sponsor

Nils Vlaeminck

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Perioperative / gastric aspiration risk

Eligibility highlights

Primary endpoint

•Prevalence of full stomach

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06292065

Org study IDProject ID 6171

Timeline

Milestones

Study first posted2024-03-04actual

Study start2024-04-16actual

Primary completion2025-05-31actual

Study completion2025-05-31actual

Last update posted2025-09-03actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Perioperative / gastric aspiration risk

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

for the semaglutide cohort are:

•Adults (>=18 years old)

•Semaglutide therapy for any indication (type 2 diabetes or weight loss)

•Semaglutide therapy at any dose

•Semaglutide therapy with any route of administration

•Semaglutide therapy administered daily or weekly

•Semaglutide therapy at any time since initiation

•Elective surgery of any kind for which general anaesthesia was planned preoperatively

•Adherence to current ASA recommendation regarding GLP-1-RA; i.e. holding semaglutide for 1 week if administered weekly or for 1 day if administered daily.

•Adherence to current ESAIC fasting guidelines; i.e. >2 hours for liquids and >6 hours for solid foods.

Inclusion criteria for the control cohort are:

•Adults (>=18 years old)

•Elective surgery of any kind for which general anaesthesia was planned preoperatively

•Adherence to current ESAIC fasting guidelines; i.e. >2 hours for liquids and >6 hours for solid foods

Exclusion criteria

for the semaglutide cohort are:

•Semaglutide not held in accordance with current ASA recommendation, i.e. held either longer or shorter than recommended.

•No adherence to current ESAIC fasting guideline

•Presence of a contra-indication to gastric ultrasound; i.e. previous gastric surgery (e.g. partial gastrectomy, gastric bypass) or hiatal hernias.

•Presence of comorbidities associated with delayed gastric emptying: scleroderma, systemic lupus erythematosus, hypothyroidism, Parkinson disease, cerebral palsy, and multiple sclerosis.

•Inability to assume the right lateral decubitus position

•Initial anaesthetic plan did not involve general anaesthesia, e.g. neuraxial or locoregional cases

Exclusion criteria for the control cohort are:

•Semaglutide or other GLP-1-RA therapy

•No adherence to current ESAIC fasting guideline

•Presence of a contra-indication to gastric ultrasound; i.e. previous gastric surgery (e.g. partial gastrectomy, gastric bypass) or hiatal hernias

•Presence of comorbidities associated with delayed gastric emptying: scleroderma, systemic lupus erythematosus, hypothyroidism, Parkinson disease, cerebral palsy, and multiple sclerosis

•Inability to assume the right lateral decubitus position

•Initial anaesthetic plan does not involve general anaesthesia, e.g. locoregional cases

Endpoints (28)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Safety / tolerability / PK

Other (unclassified)

Glycemic / diabetes

3 endpoints

Secondary/protocol endpoint/low confidence

Association between preoperative blood glucose levels and calculated gastric content

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between HbA1c levels and calculated gastric content

Time frame:Immediately preoperatively

HbA1c, change

descriptive

LOINC 4548-4

Secondary/protocol endpoint/low confidence

Association between HbA1c levels and 'full stomach'

Time frame:Immediately preoperatively

HbA1c, change

descriptive

LOINC 4548-4

Safety / tolerability / PK

4 endpoints

Secondary/protocol endpoint

Frequency of perioperative aspiration

Time frame:Immediately postoperatively

event count, event

Secondary/protocol endpoint

Prevalence of gastric symptoms

Time frame:Immediately preoperatively

descriptive, event

Secondary/protocol endpoint/low confidence

Association between nausea and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint

Association between vomiting and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Other clinical outcomes

17 endpoints

Primary/protocol endpoint

Prevalence of full stomach

Time frame:Immediately preoperatively

categorical status, event

Secondary/protocol endpoint

Frequency of changes to the anaesthetic plan

Time frame:Immediately preoperatively

event count, event

Secondary/protocol endpoint/low confidence

Calculated gastric content

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint

Prevalence of solid gastric content

Time frame:Immediately preoperatively

categorical status, event

Secondary/protocol endpoint/low confidence

Association between fasting time for solids and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between fasting time for liquids and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint

Association between dyspepsia and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint

Association between abdominal distension and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

association between semaglutide dose and calculated gastric content

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

association between semaglutide dose and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between frequency of semaglutide administration and calculated gastric content

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between frequency of semaglutide administration and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between duration of semaglutide therapy and calculated gastric content

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between duration of semaglutide therapy at current dose and calculated gastric content

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between duration of semaglutide therapy and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between duration of semaglutide therapy at current dose and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between duration of cessation of semaglutide and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Other (unclassified)

4 endpoints

Secondary/protocol endpoint/low confidence

Association between duration of cessation of semaglutide and calculated gastric content

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between preoperative blood glucose levels and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between time since onset of diabetes mellitus and calculated gastric content

Time frame:Immediately preoperatively

descriptive

Secondary/protocol endpoint/low confidence

Association between time since onset of diabetes mellitus and 'full stomach'

Time frame:Immediately preoperatively

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.